//
Yohann Loriot
Thomas Powles
Miguel ngel Climent Durn
Srikala S. Sridhar
Joaquim Bellmunt
Daniel Peter Petrylak
Jing Wang
Nuno Matos Costa
Robert J Laliberte
Alessandra Di Pietro
Petros Grivas
Cora N. Sternberg
Gustave Roussy, Universite Paris-Saclay, Villejuif, France
Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomews Hospital, London, United Kingdom
Instiuto Valenciano de Oncologia, Valencia, Spain
Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada
Department of Surgery, Division of Surgical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Yale Cancer Center, New Haven, CT
Pfizer Inc., Cambridge, MA
Pfizer, Porto Salvo, Portugal
Pfizer Inc., Cambridge, MA
Pfizer Inc, Milan, Italy
Department of Medicine, Division of Medical Oncology, University of Washington/ Fred Hutchinson Cancer Research Center, Seattle, WA
Weill Cornell Medicine, Division of Hematology & Medical Oncology, NewYork-Presbyterian Hospital, New York, NY
France
United Kingdom
Spain
Canada
United States
Portugal
Italy
PharmAbcine Inc.
Oncology (ONC)
Urology
Advanced Urothelial Carcinoma
Solute Carrier Family 12 Member 2
Carboplatin
Gemcitabine
Cisplatin
Avelumab
N/A
Randomized
III
NCT02603432
N/A
N/A